For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Expert Stresses Promotion of Technology Transfer: JPMA Symposium
January 14, 2002
- Sequelae of Cerebral Hemorrhage Deleted from Ketas Indications
January 14, 2002
- To Play a Meaningful Social Role, Become Independent, and Increase Profitability
January 14, 2002
- Long-listed Drugs Account for up to 60% of Total Sales: Top 10 Companies
January 14, 2002
- BUSINESS NEWS IN BRIEF
January 14, 2002
- Price Cutting Rates for Long-listed Drugs Likely to Be 3-tiered
January 14, 2002
- Vital-Net to Acquire Shares of Inoue Seishodo
January 14, 2002
- Home Caregivers of Dementia Patients under Severe Stress: Eisai, Pfizer Seminar
January 14, 2002
- Korosho Budget Totals \18,668.4 Bil., Up 3.2%
January 14, 2002
- Fukujin Takes Over Ethical Drugs, Lab Reagents from Inagaki
January 14, 2002
- Business Improves for Local Government-managed Hospitals
January 14, 2002
- 6 Products Including Flutide 200 Diskus Added to NHI List
January 14, 2002
- 9 Wholesalers Accept FTC Recommendation: Cartel Affair in Tohoku
January 14, 2002
- LDP to Review Operations of Univ., Social Insurance Hospitals
January 14, 2002
- OPSR, PMDEC to Be Merged: Administrative Reform
January 14, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 14, 2002
- IFN to Be Re-priced Next April
January 14, 2002
- Suntory, Sankyo Codevelop Glucagon-like Peptide-1 as Antidiabetic
January 14, 2002
- Ceiling of Copayment for the Elderly Decided
January 14, 2002
- Standard Format for Package Inserts for Medical Devices Issued
January 14, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…